Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRMD
STRONG BUYREMOVECorMedix Inc. · Healthcare · United States · $661M · Avg Vol: $12M/d
CorMedix is a commercial-stage biopharma company focused on DefenCath. While it has high quality scores (Q: 81) due to its asset-light model, it is a single-product story subject to binary regulatory and commercial adoption risks, rather than a diversified CDMO play.
COMPANY DESCRIPTION
CorMedix Inc. is a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases, particularly catheter-related infections. Its lead product candidate, DefenCath, aims to provide a novel antimicrobial solution for hemodialysis catheters, positioning the company to address a significant unmet medical need upon regulatory approval.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 65,408 | 0 | 43M | 312M | 1582.8% |
| EPS | -0.74 | -0.91 | -0.30 | 2.25 | — |
| Shares | 43M | 55M | 64M | 79M | +85.1% |
| Debt | 802,433 | 667,632 | 517,000 | 149M | 470.4% |
| Equity | 55M | 70M | 85M | 405M | 94.5% |
| Op CF | -24M | -38M | -51M | 175M | — |
| Inv CF | -4M | -17M | 21M | -308M | — |
| Fin CF | 18M | 56M | 26M | 238M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRMD | CorMedix Inc.(you) | $661M | 92 | STRONG BUY |
| ZVRA | Zevra Therapeutics, Inc. | $674M | 96 | STRONG BUY |
| RIGL | Rigel Pharmaceuticals, Inc. | $556M | 91 | STRONG BUY |
| PBYI | Puma Biotechnology, Inc. | $369M | 98 | STRONG BUY |
| ABUS | Arbutus Biopharma Corporation | $909M | 81 | STRONG BUY |
| INVA | Innoviva, Inc. | $1.6B | 98 | STRONG BUY |
| TBPH | Theravance Biopharma, Inc. | $836M | 72 | BUY |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.8B | 98 | STRONG BUY |
| MDXG | MiMedx Group, Inc. | $547M | 65 | BUY |
| SPRO | Spero Therapeutics, Inc. | $168M | 96 | STRONG BUY |
Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.2%